# Safety and Tolerability of Intravenous Administration of ICVB-1042

> **NCT05904236** · PHASE1 · TERMINATED · sponsor: **IconOVir Bio** · enrollment: 17 (actual)

## Conditions studied

- Patients With Advanced Solid Tumors

## Interventions

- **DRUG:** Treatment with ICVB-1042 administered intravenously

## Key facts

- **NCT ID:** NCT05904236
- **Lead sponsor:** IconOVir Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-01
- **Primary completion:** 2024-12-11
- **Final completion:** 2024-12-20
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Lack of Demonstrated Clinical Activity
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05904236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05904236, "Safety and Tolerability of Intravenous Administration of ICVB-1042". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05904236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*